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Renal cell carcinoma (RCC) is a common form of urologic tumor that originates from
the highly heterogeneous epithelium of renal tubules. Over the last decade, targeting
therapies to renal cancer cells have transformed clinical care for RCC. Recently, it was
proposed that renal cancer stem cells (CSCs) isolated from renal carcinomas were
responsible for driving tumor growth and resistance to conventional chemotherapy
and radiotherapy, according to the theory of CSCs; this has provided the rationale for
therapies targeting this aggressive cell population. Precise identification of renal CSC
populations and the complete cell hierarchy will accurately inform characterization of
disease subtypes. This will ultimately contribute to more personalized and targeted
therapies. Here, we summarize potential targeting strategies for renal cancer cells
and renal CSCs, including tyrosine kinase inhibitors, mammalian target of rapamycin
inhibitors (mTOR), interleukins, CSC marker inhibitors, bone morphogenetic protein-2,
antibody drug conjugates, and nanomedicine. In conclusion, targeting therapies for RCC
represent new directions for exploration and clinical investigation and they plant a seed
of hope for advanced clinical care.
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INTRODUCTION
Renal cell carcinoma (RCC) is not a single entity, but rather comprises a population of tumors that
originate from the highly heterogeneous epithelium of renal tubules. According to the Heidelberg
classification of renal cell tumors, histologic subtypes of RCC include clear cell adenocarcinoma,
which is the most common form of RCC, chromophobe collecting duct carcinoma, papillary
carcinoma, and unclassified carcinomas (Kavacs et al., 1997). Among urologic tumors, RCC has
the highest cancer-specific mortality rate, and the 5-year survival rate for patients with metastatic
disease is only 12% (Siegel et al., 2015). In addition, RCC accounts for approximately 3.8%
of all adult human malignancies, with an annually increasing incidence (Koul et al., 2011).
Chemotherapy is one of the principal modes of cancer treatment; however, its effectiveness is
limited by drug resistance. Moreover, RCC is also resistant to radiation, and weakly sensitive to
immunotherapeutic agents, such as interleukin (IL)-12 and interferon (INF)-α. Tumor recurrence
occurs in 40% of patients after curative surgical resection (Koul et al., 2011). To date, RCC is still a
tumor of unpredictable presentation and poor clinical outcome.
Cancer stem cells (CSCs) are a small population of cancer cells responsible for resistance to
radiation and chemotherapy. There are numerous mechanisms that may explain chemo-radiation
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resistance of CSC, including their assumed quiescence, high
drug eﬄux capacity, residing in hypoxic niches, and the up-
regulation of DNA damage response and repair genes (Shukrun
et al., 2014). They are also responsible for metastasis, tumor
development, disease progression, and disease recurrence. They
are characterized by an extraordinary capacity for unlimited cell
division and maintenance of the stem cell pool in the tumor.
They keep dividing until they build terminally differentiated,
specialized cells due to unlimited self-renewal and multipotency
toward heterogeneous progeny (Visvader and Lindeman, 2008;
Clevers, 2011). There is accumulating evidence that selective
targeting of CSCs is possible and that CSCs can be selectively
eradicated to improve the survival and quality-of-life in cancer
patients (Yilmaz et al., 2006; Smith et al., 2010).
There is common consent that renal CSCs have tumorigenic
ability and that they are resistant to chemo- and radio-therapy,
providing the rationale for therapies targeting this aggressive
cell population. The development of personalized treatment
strategies is supported by comprehensive molecular analyses
of RCC (Gerlinger et al., 2012; Bielecka et al., 2014) and
pharmacogenomics studies of putative CSCs (Crea et al., 2011).
In terms of selective markers for CSCs in clear cell RCC
(ccRCC), CD105, a prominent marker, can distinguish a rare
subpopulation of cells that exhibit CSC properties (Bussolati
et al., 2008, 2011). CD133, also known as prominin-1, is
a transmembrane glycoprotein that has been investigated as
another putative marker of renal progenitor cells in the adult
human kidney; it appears to be non-tumorigenic and it is
expressed in resident adult kidney progenitors cells (Bruno et al.,
2006). The side population (SP), which can be identified using
a Hoechst 33342 dye eﬄux assay, can also express putative CSC
markers, but it has not been reliably demonstrated that SP also
displays CSC properties (Addla et al., 2008).
Specific CSC markers could represent valuable tools for
targeting these cells with drugs or immunotoxins. Investigation
of intracellular pathways and genetic abnormalities may lead
to the development of efficient therapeutic strategies targeting
renal CSCs (Bussolati et al., 2013). The development of a slew
of rationally designed targeted therapies that inhibit vascular
endothelial growth factor (VEGF) receptor and mammalian
target of rapamycin (mTOR) pathways has contributed to
the systemic management of RCC. Furthermore, molecular
targeting nanomedicine-based approaches, which can control
drug delivery and release more efficiently, can effectively
inhibit multiple types of CSCs. In this review, the author
summarizes the potential targeting strategies underlying tyrosine
kinase inhibitors, mTOR inhibitors, interleukins, CSC marker
inhibitors, bone morphogenetic protein-2 (BMP-2), antibody
drug conjugates (ADCs), and nanomedicine that can target renal
cancer cells and renal CSCs to treat RCC more efficiently.
NORMAL RENAL STEM CELLS
According to the “hierarchical” theory, the three most common
RCC histologic subtypes (undifferentiated, clear-cell, papillary
carcinomas) may arise from the stem cell pool of the adult kidney
or from the deriving progenitors. Whereas the Wilm’s tumor
may arise from the embryonic renal stem cell compartment
(Bussolati et al., 2011). To isolate and characterize of renal
stem cells, several methods have been attempted. These include
pulse-chase labeling of slow cycling cells, dye exclusion assay,
FACS/magnetic bead separation by stem cell surface markers, and
selective culture conditions for renal dissociated tissue (Gupta
et al., 2006; Sagrinati et al., 2006; Gupta and Rosenberg, 2008;
Ronconi et al., 2009). The isolated cells exhibited multipotent
differentiation capacity in vitro. Importantly, they can integrate
into injured renal tubules. The parietal epithelium of Bowman’s
capsule, which give rise to both podocytes and tubules, has been
suggested harbor intrarenal stem cells. In addition, multipotent
CD133+/CD24+ stem cells have been further isolated from the
Bowman’s capsule. CD133+ renal progenitor cells have been
characterized in the renal cortex from the tubule/interstitium
(Sagrinati et al., 2006; Lindgren et al., 2011). Humphreys et al.
(2008) evaluated the degree of involvement by extratubular
cells during renal regeneration. Their results demonstrated that
the proliferating intratubular epithelium accounts for tubular
regeneration (Humphreys et al., 2008). However, the putative
connection between renal stem cells and renal carcinomas is
still not clarified due to the unequivocal understandings of the
renal stem cell. For example, numerous technical limitations
hindered the efforts for the isolation and characterization of renal
stem cells; and there are different stem cell subpopulations with
restricted differentiation potential in kidneys.
RENAL CANCER STEM CELL MARKERS
Multiple studies have been designed to isolate and characterize
the CSC population in RCC using stem cell markers, which
are considered targets in CSC therapy. A better understanding
of stem cell markers and the related signaling pathways that
contribute to tumor progression and metastasis is important for
the development of strategies for CSC-targeting treatments.
STEM CELL SURFACE MARKERS IN
RENAL CSCs
CD105, also called endoglin, is a receptor for transforming
growth factor-β (TGF-β) and is expressed on the cell surface.
It regulates cellular proliferation, differentiation, and migration,
and is therefore important for angiogenesis (Dallas et al.,
2008). By magnetically sorting cells in RCC specimens, Bussolati
et al. (2008) separated a subpopulation of cells expressing the
mesenchymal marker CD105. This finding is consistent with
the mesenchymal origin of the kidney and the mesenchymal
phenotype of stem cells found in normal rodent kidney as
well as in the human embryo; these cells represented less
than 10% of the total tumor mass (Bussolati et al., 2008).
They could differentiate into epithelial cells both in vitro and
in vivo. In vivo, CD105-positive (CD105+) cells could display
the tumor-initiating activity that as few as 100 cells could
generate transplantable tumors. In vitro they could differentiate
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into both epithelial and endothelial cells. These results indicated
that the CD105+ cells may originate from resident renal stem
cells with mesenchymal characteristics. In addition, other studies
have reported that CD105+ cells are present in the established
RCC cell lines 786-O, 769-P, ACHN, Caki-1, Caki-2, SMKTR2,
SMKTR3, and RCC-6 (Khan et al., 2012, 2013) and that there
is no relationship between CD105 and gender, age, cell type,
or tumor size (Sandlund et al., 2006). More recently, a CSC
differentiation strategy test was conducted on CD105+ CSCs to
aid in their isolation from human renal carcinomas. CD105+
CSCs differentiated into cells that expressed epithelial markers
(E-cadherin and pan-cytokeratin) when they were treated with
recombinant human IL-15 (rhIL-15) at a concentration of
10 pg/mL. Compared with severe combined immunodeficiency
(SCID) mice that were injected with untreated CD105+ CSCs,
SCID mice with IL-15-treated CSCs demonstrated significantly
higher levels of apoptosis in differentiated epithelial cells
following treatment with vinblastine or paclitaxel (Azzi et al.,
2011). In patients, high CD105 levels are associated with higher
tumor stage and CD105 is a crucial indicator of clinical outcome.
Therefore, further investigation of potential therapeutic targets is
warranted.
CD133, a five transmembrane domain glycoprotein, belongs
to the prominin family. It contains two large extracellular
and two small intracellular loops (Grosse-Gehling et al., 2013).
Currently, it serves as a useful marker for the isolation and
characterization of various types of stem and progenitor cells
in human tissues. Using a specific monoclonal antibody, human
CD133 was first isolated from hematopoietic stem cells (HSCs)
which consisted of various kinds of stem/progenitor cells and
differentiated cells. The CD133+ cell population can influence
tumor vascularization and angiogenesis, and it is also expressed
in normal adult human kidney cells (Bussolati et al., 2005). Zhang
et al. (2013) observed that CD133 expression was associated
with stage, histological type, tumor location, and tumor grade.
Bruno et al. (2006) demonstrated that CD133+ progenitor cells
derived from human RCC contributed to tumor vascularization.
High expression of CD133 is associated with a macro-/micro-
cystic pattern, non-metastatic disease, and non-sarcomatoid
changes (Kim et al., 2011). CD133 may have a role in risk
stratification; its overexpression was associated with longer
survival in patients with ccRCC. On the other hand, low CD133
expression is an independent predictor of poor disease-specific
survival (DSS) and progression-free survival (PFS) (Costa et al.,
2012). Additionally, CD133 may be involved in both epithelial
and endothelial differentiation in vitro and in vivo. However,
CD133+ cells were not able to induce carcinoma development
after subcutaneous injection into SCID mice, indicating non-
tumorigenic potential. This result is in contrast with the idea
that renal CSCs arise from renal progenitors expressing the
CD133 marker (Bussolati et al., 2011). Interestingly, injection
of CD133+ cells with the RCC cell line K1 into SCID mice
would lead to significant tumor growth and progression. Inside
the tumor, the newly formed vessels expressed both human
CD31 and human HLA class I. The resultant tumor vessels
via the differentiation of CD133+ progenitor cells plus K1
cells was later confirmed by fluorescence in situ hybridization
for human origin of chromosome X (Bruno et al., 2006).
However, clinical significance of CD133 expression in human
RCC is inconsistent. In addition, no study showed that CD133
can serve as a therapeutic target for renal cancer or renal
CSCs because of its wide expression in kidney progenitor cells
probably. But many papers have reported targeting CD133+
cells therapy for other cancers. More recently, Qi et al.
(2016) loaded chemotherapeutic antitumor drugs and small
interfering RNA (siRNA) against CD133+ into mesoporous silica
nanoparticles (MSNPs) with thermo/pH-coupling sensitivity and
site-specificity. These MSNPs successfully inhibited its growth
in vivo in a laryngeal cancer mouse model by eliminating
CD133+ cells (Qi et al., 2016).
CD44, a single-chain transmembrane glycoprotein, binds
primarily to the extracellular glycosaminoglycan hyaluronan, an
adhesion molecule for the extracellular matrix (Ponta et al.,
2003; Hiraga et al., 2013). This interaction is considered a
signaling platform for integrating cellular microenvironmental
cues with growth factor and cytokine signals. Moreover, Debeb
et al. (2010) described CD44+/CD24− cells with several CSC
features in the human embryonic cell line 293T. Although
CD44+ human carcinomas are very resistant to therapy and
highly malignant, there is still some debate on the role of
CD44 in CSCs. Undoubtedly, metastatic potential is improved
by the expression of CD44, and metastatic properties are often
linked to CSCs (Toole, 2009; Zhang et al., 2013). Furthermore,
CD44+/CD24− cells in three-dimensional (3D) spheres were
reported to be resistant to radio- and chemo-therapy (Debeb
et al., 2010). In another report, Lim et al. (2008) suggested
that CD44 expression in RCC could be used to inform the
appropriate therapy and provide useful prognostic information
in both primary and metastatic RCC. Meanwhile, a meta-
analysis of the literature showed that CD44 was a poor
prognostic marker for 5-year overall survival and that high
CD44 expression levels were associated with high Fuhrman
grade and recurrence (Li et al., 2015). A new study proposed
by Ma et al. (2016) proposed a possible mechanism for CD44
upregulation. They found that a third of the tumor samples
analyzed expressed CD44, and that while CD44 expression was
not associated with clinical outcome, it was associated with
a high density of tumor-associated macrophages (Ma et al.,
2016).
CXCR4 is a 352-amino acid rhodopsin-like G-protein coupled
receptor (GPCR) which binds selectively to the CXC chemokine
stromal cell-derived factor-1 (SDF-1, also known as CXCL12).
CXCR4 is expressed on all kinds of tissues and organs and
normal stem cells. Therefore, it is one of the best researched
chemokine receptors (Weitzenfeld and Ben-Baruch, 2014). The
expression of CXCR4 has a significant negative predictive value
on PFS in patients treated with IFN-α (Li et al., 2011). Low or
absent CXCR4 expression is predictive of a good response to
sunitinib therapy, while CXCR4 expression is associated with
a poor response to sunitinib in metastatic ccRCC (D’ Alterio
et al., 2012). Furthermore, the CXCL12-CXCR4 signaling axis
plays an important role in the homing of normal stem cells
(Lapidot and Kollet, 2002). This CXCL12-CXCR4 axis is involved
in the trafficking/metastasis of CSCs to various organs when
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CXCR4 is expressed; CXCR4 is also highly expressed in the lymph
nodes, lungs, liver, and bone (Kucia et al., 2005; Mukherjee and
Zhao, 2013). Gassenmaier et al. (2013) compared the capacity
of two RCC cell lines, RCC-26 and RCC-53, to form spheres
in vitro and to establish tumors in vivo, and observed that
CXCR4 was present only in the more tumorigenic RCC-53 cell
line (Gassenmaier et al., 2013). Micucci et al. (2015) recently
reported that the self-renewing ability of CXCR4+ spheres was
enhanced before the upregulation of hypoxia-inducible factor 2α
(HIF-2α) in the RCC cell lines Caki-1, Caki-2, 786-O, and 769-P.
Knockdown of HIF-2α abolished CXCR4+ sphere formation and
expression, and inhibition of HIF-2α abrogated tumor growth
in vivo, proving that HIF-2α activation plays an important role
in CSC expansion.
INTRACELLULAR MARKERS IN RENAL
CSCs
Cancer stem cells are likely derived from differentiated
cancer cells through various mechanisms, including cellular
interactions, tumor niche signals, and epithelial to mesenchymal
transition (EMT) (Schieber and Chandel, 2013; Pattabiraman
and Weinberg, 2014). EMT is a highly conserved cell process
involved in normal embryogenesis and tissue repair (Liu and
Fan, 2015). Recently, numerous studies have shown that EMT
plays a momentous role in tumor progression. Through EMT,
tumor cells can obtain stem cell-like characteristics, through
the acquisition of mesenchymal properties. The results of
accumulating studies have indicated that a promising link
exists between EMT and the CSC phenotype. Lichner et al.
(2015) reported that isolated RCC spheres displayed CSC-like
properties that were linked to the TGF-β-EMT axis. Additionally,
recent research has suggested that EMT can be artificially
induced during the culture of the RCC cell lines ACHN and
786-O, enriching their stem cell-like characteristics (Liu and
Fan, 2015). ACHN and 786-O cells treated with 50 ng/ml
tumor necrosis factor-α lost their epithelial morphology and
acquired a mesenchymal appearance with increased expression
of mesenchymal protein markers such as vimentin, slug, and
ZEB1.
Li et al. (2014) proposed a method to reverse the EMT process
and inhibit CSC-like features in RCC. According to their results,
honokiol extract isolated from magnolia bark – a multifunctional
antiangiogenic and natural antitumor agent – can simultaneously
abrogate proliferation, reverse EMT (as determined by an
increase in epithelial markers and a decrease in mesenchymal
markers), and significantly inhibit the CSC properties of RCC
cells in vivo (tumorigenicity) and in vitro (sphere formation,
invasion/migration, SP) (Fried and Arbiser, 2009; Li et al.,
2014; Weygant et al., 2015). Of note, a recent study found
that high expression of the PIK3R1 protein was associated with
RCC progression and metastasis (Lin et al., 2015). A PIK3R1
knockout functional study demonstrated that PIK3R1 plays a
crucial role in RCC cell proliferation and migration; maintenance
of a mesenchymal morphology; and the incremental expression
of EMT-related factors in vitro (Lin et al., 2015). By analyzing data
in The Cancer Genome Atlas’ Kidney Renal Clear Cell Carcinoma
(TCGA KIRC) dataset, Weygant et al. (2015) demonstrated
that doublecortin-like kinase 1 (DCLK1) regulates EMT and
maintains stemness features; DCLK1 is overexpressed in RCC
tumors regardless of disease stage. In primary RCC-Caki-2 cells,
silencing of the DCLK1 gene using DCLK1 siRNA resulted
not only in decreased expression of EMT transcription factors
(SNAI1, SNAI2, TWIST1, ZEB1, and Vimentin), but also reduced
expression of the pluripotency and stemness factors MYC,
Nanog, Oct-4, Sox-2, and aldehyde dehydrogenase (ALDH) 1A1
(Weygant et al., 2015). These results corroborated the finding that
DCLK1 knockdown can inhibit the invasive and metastatic ability
of RCC cells.
Recently, SP cells from an RCC cell line were genetically
modified to knock out DnaJ (Hsp40) homolog, subfamily
B, member 8 (DNAJB8) and examine its function in the
tumorigenicity of RCC (Yamashita et al., 2016). Compared
with non-SP RCC cells, the SP is distinguishable by increased
sphere-forming ability in vitro, enhanced proliferative potential,
and greater expression levels of β-catenin, Sonic Hedgehog,
Notch, and Pax-2 stem cell markers. Furthermore, the SP had
an abundance of ALDH-positive cells, suggesting that ALDH
enzymatic activity may be associated with the SP (Ueda et al.,
2013). DNAJB8 knockout cells displayed a decreased ratio of SP
to non-SP cells and reduced sphere-forming ability, indicating
that DNAJB8 contributes to CSC-like phenotype of RCC
(Nishizawa et al., 2012). This study also demonstrated that the
overexpression of DNAJB8 increased the proportion of SP cells,
boosted tumor-initiating ability, and enhanced the expression of
stem cell markers (Nishizawa et al., 2012). Furthermore, western
blots and immunostains of SP cells have shown that these cells
express DNAJB8 protein, indicating stem cell-like phenotypes. In
DNA vaccination experiments, DNAJB8, as a potential marker of
RCC CSCs, was considered as an immunotherapeutic target.
MicroRNAs (miRNAs) have been described in various
cancers, including prostate cancer, glioblastoma, and breast
cancer (Liu and Tang, 2011; Shimono et al., 2015). They are
non-coding, small, single-stranded RNA molecules, that play a
significant role in posttranscriptional gene regulation and are
essential in sustaining normal pluripotent embryonic stem cells
in mice (Melton et al., 2010). Analysis of the effect of miR-17
on RCC spheres with cancer stem-like properties revealed that
spheres from ACHN and Caki-1 cell lines demonstrated greater
tumorigenic capacity and elevated expression of mesenchymal
markers and stem cell in vivo (Lichner et al., 2015). miR-17
overexpression hindered sphere formation by modulating the
TGF-β-EMT axis (Petrocca et al., 2008). Interestingly, miR-
17 inhibition led to increased colony formation in ACHN
and Caki-1 cell lines, which demonstrated that miR-17 could
regulate the self-renewing properties of the cells; inhibition also
enhanced expression of mesenchymal markers and cancer stem
markers (Giron-Michel et al., 2012). In summary, miR-17 belongs
to a carcinogenic miRNA cluster necessary for development
and homeostasis (Concepcion et al., 2012). Further research
on miRNAs in RCC tumor promotion, therapy resistance,
metastasis, progression and relapse will contribute to a better
understanding of RCC tumor biology (Liu and Tang, 2011).
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POTENTIAL TARGETING STRATEGIES
In the view of the resistance to chemo- and radio-therapies
(Lyakhovich and Lleonart, 2016) and the weak response
to immunotherapeutic agents (Di Lorenzo et al., 2010)
demonstrated by RCC, more attention has been paid to the
development of potential approaches to target renal CSCs. Over
the past several years, more and more encouraging data have
demonstrated proof of principle that targeting CSCs could
block the pathways associated with drug resistance, disease
progression, aggressiveness, and metastasis, and may lead to
complete and durable regression; this could improve treatment
outcomes for patients with RCC and affect prognosis (Figure 1)
(Sehl et al., 2009; Smith et al., 2010; Azzi et al., 2011). In
particular, strategies that can target markers expressed on the
cell surface or disrupt specific signaling pathways are considered
ideal targeting strategies for CSCs. Identification of potential
targets in the renal CSC microenvironment or nanocarriers for
delivery of active compounds may also result in the development
of efficient strategies for the elimination of CSCs. Potential
targeting strategies for renal cancer cell and renal CSCs are
summarized in the next section.
TYROSINE KINASE INHIBITORS
Tyrosine kinase signaling is a unique biochemical mechanism
utilized by intra- and inter-cellular communication pathways
in metazoans. Abnormal tyrosine kinase signaling leads to
various cancers, as well as other diseases (Levitzki, 2013).
Tyrosine kinase inhibitors (TKIs) are novel therapies that
target specific cellular signaling pathways by primarily
blocking tyrosine kinase receptors that are involved in the
progression of several tumors, including RCC (Eichelberg
et al., 2008; Albiges et al., 2012). By inhibiting the activity
of growth factor receptors, in particular, VEGF receptor,
platelet-derived growth factor (PDGF) receptor, and the stem
cell factor c-KIT receptor, TKIs can significantly affect tumor
angiogenesis and/or tumor cell proliferation. Sunitinib and
sorafenib, commercially available TKIs, are associated with good
treatment response and are tolerable in RCC patients. However,
severe side effects including cardiotoxicity, hypothyroidism,
hypertension, fatigue, hair depigmentation, hand-foot syndrome,
and gastrointestinal perforation have been observed (Cohen
and Oudard, 2012; Sternberg et al., 2015; Jang et al., 2016).
Importantly, Czarnecka et al. (2015b) recently reported that
a much more severe side effect, chronic myeloid leukemia
(CML), developed in some patients with ccRCC during
TKI treatment. The authors described a potential molecular
mechanism of action of TKIs on bone marrow cells that may be
responsible, in part, for development of CML (Czarnecka et al.,
2015b).
Several pathways involved in oncogenesis are blocked by TKIs,
including pathways in growth, survival, proliferation, and, most
importantly, differentiation and apoptosis. However, TKIs have
not been considered a primary therapy for CSCs because they
lack sufficient selectivity for this peculiar cell type. Poor selectivity
is also the main reason for many of the side effects of TKIs.
Recent studies have demonstrated that TKIs can decrease the
proliferation rate of renal CSCs, but that the efficacy of the
growth inhibition was limited by hypoxic conditions and 3D
intratumoral cell–cell interactions (Czarnecka et al., 2016). More
evidence is needed to prove that TKIs have an inhibitory effect on
renal CSCs and to delineate their mechanism of action in this cell
type. Thus, a better understanding of this effect will lead to more
successful therapies for RCC.
mTOR INHIBITORS
Mammalian target of rapamycin inhibitors, an important
therapeutic target for RCC, permits protein translation that
drives cell growth, proliferation, and the production of
angiogenic growth factors including HIF-1, VEGF, and PDGF. In
RCC, mTOR is stimulated by a VEGF-induced phosphorylation
cascade, which involves PI3K and Akt (Czarnecka et al., 2015a;
Xia and Xu, 2015). Activation of the mTOR pathway leads to
translation of proteins involved in cell cycle progression and
HIF-1α expression, which is associated with RCC pathogenesis.
On the other hand, mTOR inhibitors whose mechanism of
action is distinct from that of the TKIs mentioned above,
halt tumor cell growth and angiogenesis by down-regulating
HIF expression and blocking proliferation and survival signals
downstream of the VEGF receptor (Kornakiewicz et al., 2014;
Liu et al., 2016). Temsirolimus and everolimus are orally
administered mTOR inhibitors used for targeted therapy in
metastatic renal cell carcinoma (mRCC). Clinical trials in
patients with mRCC showed that treatment with temsirolimus
or everolimus prolonged PFS relative to the placebo in
patients with mRCC that had progressed on other targeted
therapies (Motzer et al., 2008; Negrier, 2008). To date, it
is unknown if mTOR inhibitors may prove to be selective
enough for renal CSCs and research on their selectivity
is ongoing. Interestingly, some clues can be found from a
number of recent studies on mTOR inhibitors that eradicated
the CSC populations in nasopharyngeal carcinoma, colon
cancer, and glioblastoma multiforme, among other cancers
(Francipane and Lagasse, 2013; Sami and Karsy, 2013; Kolev
et al., 2015; Yang et al., 2015), which may indicate future
directions for designing novel drugs targeting mTOR for renal
CSCs.
The emerging perspective for mTOR inhibitors in RCC
treatment involves combination therapies targeting both renal
cancer cells and renal CSCs. This approach requires analysis of
multiple overlapping signaling networks to carefully preselect
suitable molecular targets on these cells (Czarnecka et al., 2015a).
However, the researchers are facing a greater challenge for trying
to find new molecular targets since current knowledge on the
systems biology of renal cancer cells and renal CSCs are far
from enough. Therefore, attempts have been made to develop
a combination treatment consisting of mTOR inhibitors and
TKIs. A combination of everolimus and sorafenib was used
in the treatment of mRCC; this combination had acceptable
toxicity levels and demonstrated antitumor activity in previously
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FIGURE 1 | Conventional therapy and targeting therapy for cancer stem cells (CSCs) in renal cell carcinoma (RCC). Conventional therapy in RCC can
reduce tumor size. However, CSCs are resistant to conventional therapies and induce tumor relapse through self-renewal and division. Targeted therapy for CSCs
provides a new direction to eradicate the tumor.
untreated patients with mRCC (Amato et al., 2012). Another
combination consisting of temsirolimus plus bevacizumab, an
mTOR inhibitor, and a VEGF inhibitor, showed encouraging
evidence in a Phase 1 trial for the treatment of mRCC.
However, the results of the Phase 2/3 trial did not show a
sufficient improvement in efficiency (Rini et al., 2014; Jobard
et al., 2015). Additional combinations using mTOR inhibitors
together with other targeted agents can more effectively inhibit
mTOR and/or block signaling in multiple pathways, such as the
PI3K/Akt/mTOR and Ras/Raf/MEK/Erk pathways (Asati et al.,
2016; McKay et al., 2016).
Indeed, it remains to be seen if novel combination therapies
using mTOR inhibitors can target both renal cancer cells and
renal CSCs. Several studies have successfully used combination
treatments to target CSCs in other cancers. A combination
treatment in glioblastoma multiforme uses differentiating agents
with mTOR pathway inhibitors to target CSCs, thereby targeting
the ERK1/2 pathway. This underscores the importance of
including differentiating agents along with inhibitors of mTOR
pathways in the treatment of glioblastoma multiforme (Friedman
et al., 2013). Similar studies confirmed that mTOR inhibitors
combined with other agents represented promising therapeutic
strategies to eradicate CSCs in breast cancer, liver cancer, and
pancreatic cancer (Zhu et al., 2012; Gedaly et al., 2013; Sharma
et al., 2015).
Beyond temsirolimus and everolimus, there have been
a slew of second generation mTOR inhibitors, such as
mTORC1/mTORC2 inhibitors and mTOR/PI3K dual inhibitors,
that have shown promising activity in pre-clinical studies or
have entered clinical trials (Vilar et al., 2011; Zhang et al., 2011).
According to the NIH database1, over 50 clinical trials, ongoing or
completed, proposed to apply mTOR inhibitors for the treatment
of RCC. Regardless of the potential effect of novel mTOR
inhibitors on CSCs, it may be necessary to combine them with
other drugs to ensure an antiangiogenic effect. Combinatorial
control of cell signaling still seems to be more successful than
monotherapy.
INTERLEUKINS
The interleukins act as ligands and regulate many physiologic
and pathophysiologic processes by binding to their receptors and
1https://clinicaltrials.gov/
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activating or inhibiting several intracellular pathways. This has
led to the investigation of these pathways as potential therapeutic
targets. Interleukins-1, -2,-3, -4, -6, -11, -12, -15, -18, and -21 have
been tested in the clinic with variable rates of success and failure
as cancer therapeutics (Aulitzky et al., 1994; Dranoff, 2004). IL-2-
based immunotherapy has been approved by the FDA and is the
standard therapy for advanced RCC, even though poor response
and severe toxicity can occur in some cases (Di Lorenzo et al.,
2010). The response rate with IL-2 treatment ranges from 7 to
27%. The best response was achieved in patients with favorable
Motzer criteria, ccRCC, and lung metastases only. Long-term
complete responders have been reported with high-dose bolus
IL-2 regimens in ccRCC (Ljungberg et al., 2010).
IL-15 exhibits a therapeutic index superior to that of IL-
2, and is commonly used in renal cancer treatment (Steel
et al., 2012; Waldmann, 2014). Although some of the biological
properties of IL-15 overlap with those of IL-2, such as the
activation of natural killer (NK) cells and CD8 T cells, IL-15
is not associated with capillary leak syndrome or activation-
induced cell death, nor does it have a major effect on the
number of functional regulatory T cells (Waldmann et al.,
2011). Systemic administration of rhIL-15 showed less toxic
effects than IL-2, indicating that multiple daily infusions of
rhIL-15 could be administered to patients with metastatic
malignancies (Munger et al., 1995; Waldmann et al., 2011).
Recently, IL-15 was shown to induce differentiation of CD105+
renal CSCs isolated from human renal carcinomas (Azzi et al.,
2011). Based on previous studies that had shown that IL-15
acted as a survival factor in renal tubular epithelial cells via
autocrine-paracrine loops, the authors identified IL-15 as a
potential candidate (Shinozaki et al., 2002). Other studies have
shown that IL-15 upregulates E-cadherin expression through
γc chain signaling pathway and blocks EMT in renal tubular
epithelial cells (Figure 2) (Giron-Michel et al., 2012, 2013).
Azzi et al. (2011) demonstrated that IL-15 can induce the
stable epithelial differentiation of renal CD105+ CSCs, thereby
generating a differentiated non-tumorigenic cell population that
is more sensitive to the chemotherapeutic drugs vinblastine and
paclitaxel, compared with the parental CSCs. RCC cells do not
secrete IL-15, suggesting that the loss of intratumoral IL-15
secretion could be a protection mechanism for CSC stemness
(Trinder et al., 1999; Azzi et al., 2011). Finally, self-renewal along
with tumor sphere-forming ability was blocked in renal CSCs
treated with IL-15, indicating the potential utility of IL-15 as a
differentiation therapy in RCC. These observations support that
IL-15 is a key factor directing the epithelial differentiation of renal
CSCs. Moreover IL-15 therapy meets the criteria of CSC targeting
treatment strategy: depletion of CSCs pool and generation of
differentiated non-tumorigenic cells with increased sensitivity to
chemotherapeutic drugs. Azzi et al. (2011) proposed two IL-15-
based therapy strategies to target renal CSCs: (1) induction of
paracrine IL-15 secretion by renal CSCs or neighboring cells
mediated by gene transduction; (2) direct administration of IL-
15 to the tumor tissue or delivery to the CSCs by coupling
to peptides or antibodies which target to renal cancer cells or
renal CSCs markers. Due to the potential dual effect of IL-15
on both the differentiation of renal CSCs and the activation
of an antitumor immune response, this therapy strategy could
provide the foundations for the enhancement of renal carcinoma
treatment. A phase 1 study of the effect of intravenous human
rhIL-15 in the treatment of mRCC has been completed recently
(NCT01021059)2.
IL-21, a novel cytokine with structural and sequence
homology to IL-2 and IL-15, has been studied extensively both
in vitro and in vivo and evaluated in Phase 1 and 2 trials
(NCT00617253, NCT00389285, and NCT00095108) in mRCC.
The data from these trials indicated that IL-21 has an acceptable
safety profile and encouraging single agent activity in early phase
RCC and melanoma clinical trials (Hashmi and Van Veldhuizen,
2010). To date, it has not been shown if IL-21 has utility as
a targeted therapy, similar to IL-15, in renal CSCs. Further
investigation is needed to determine the effect of IL-21 on renal
cancer cells or CSCs in the treatment of RCC.
CSC SURFACE MARKER INHIBITORS
CD105/Endoglin Inhibitors
Renal CSCs isolated from nephrectomy specimens express
CD105/endoglin, allowing valuable therapeutic target for the
tumor vasculature (Bussolati et al., 2008). The identification of
CD105/endoglin as a specific CSC marker was a solid buildup
for treatment of RCC and its biology significance has been
discussed as above. CD105 expression is also upregulated by
hypoxia through induction of HIF-1α or following inhibition
of the VEGF pathway (Seon et al., 2011). It is appealing to
consider that the identification and inhibition of CSC markers
may result in greater treatment efficacy in RCC. The evaluation
of anti-CD105/endoglin antibodies in RCC is a logical next
step.
TRC105, a novel chimeric IgG1 anti-CD105/endoglin
monoclonal antibody with high avidity, induces antibody-
dependent cellular cytotoxicity and apoptosis in human
umbilical vein endothelial cells and CD105+ tumor cells (Rosen
et al., 2012). Notably, the angiogenesis inhibition of TRC105 was
much more impressive than the inhibition of human endothelial
proliferation in vitro, emphasizing the importance of assays that
mimic the interplay between endothelium and perivascular cells
during angiogenesis (Rosen et al., 2014). TRC105 is currently
being evaluated for the treatment of RCC in Phase 1 and 2 trials
(NCT01727089 and NCT01806064)2 (Choueiri et al., 2015a;
Dorff et al., 2016). Encouraging preliminary results showed that
administration of 10 mg/kg TRC105 was well tolerated with
axitinib in patients with RCC. In addition, no TRC105-associated
dose-limiting toxicities were observed with doses ranging from
8 to 10 mg/kg. Most importantly, the combination of TRC105
and axitinib increased the overall response rate and doubled PFS
compared with axitinib as a single agent (Choueiri et al., 2015b).
CXCR4 Inhibitors
The CXCL12/CXCR4 biological axis, also discussed above, is
another potential therapeutic target for RCC. It is believed
2https://clinicaltrials.gov/
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FIGURE 2 | Interleukin (IL)-15-based targeting strategy for renal CSCs. CD105+ CSCs identified and isolated from human renal carcinomas were cultured
with 10 pg/mL recombinant human IL-15, which induced the loss of stem cell markers and induced epithelial differentiation via the signaling pathway (IL-15Rαβγ
chains). The differentiated CD105+ CSCs lost their tumor-initiating and self-renewing abilities. Endogenous IL-15-based autocrine loops were activated to induce
permanent epithelial differentiation.
to play significant roles in tumorigenesis and metastasis
(Gassenmaier et al., 2013). Small-molecule antagonists and other
strategies to downregulate CXCR4 expression have already been
developed; these represent potential therapeutic strategies to
inhibit tumors metastasis and enhance the survival of patients
with RCC. AMD3100 (commonly known as plerixafor, trade
name Mozobil) is a specific CXCR4 antagonist that inhibits
cancer cell tumorigenesis, disrupts the CSC niche, and sensitizes
CSCs to chemotherapy (Yang and Wechsler-Reya, 2007). Distinct
from the commonly used method for the design of antagonists,
three cyclic peptides were designed by Portella et al. (2013) as
new CXCR4 antagonists. These three CXCR4 inhibitory peptides
were proven to be effective in inhibiting CXCR4-dependent
migration and binding, P-ERK1/2-induction, calcium eﬄux,
and tumor growth of renal cancer cells (Portella et al., 2013).
LY2510924 is a peptide antagonist of CXCR4 from Eli Lilly and
Company and is currently in Phases 1 and 2 testing to evaluate
its safety and efficacy in RCC (NCT01391130)3. Preliminary
data suggested that adding the CXCR4 inhibitor LY2510924
to sunitinib as a first-line treatment for metastatic RCC was
tolerated but did not improve efficacy (Hainsworth et al., 2015,
2016).
3https://clinicaltrials.gov/
RNA interference (RNAi), which has been proven to be
a powerful tool for suppressing CXCR4 gene expression, has
also been used as a treatment strategy in RCC. Wang et al.
(2012b) developed recombinant CXCR4-RNAi plasmids that
they transfected into RCC A-498 cells overexpressing CXCR4
in vitro. Specific downregulation of CXCR4 by RNAi inhibited
cell growth, invasion, and migration and induced cell apoptosis
in RCC in vitro (Wang et al., 2012b).
Ierano et al. (2014) demonstrated that mTOR activation
was specifically inhibited by CXCR4 antagonists in human
renal cancer cells. CXCR4 antagonists seem to regulate mTOR
signaling in renal cancer cells, offering new therapeutic
opportunities and targets to overcome resistance to mTOR
inhibitors (Ierano et al., 2014). Similarly, a newly discovered
CXCL12 receptor, CXCR7, is highly expressed in RCC patients,
indicating that CXCR7 may be useful a novel surface marker
and therapeutic target for RCC (Maishi et al., 2012; Wang et al.,
2012a).
BONE MORPHOGENETIC PROTEIN-2
Bone morphogenetic protein-2 is a member of the TGF
superfamily. It regulates various cellular processes including cell
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differentiation, proliferation, morphogenesis, cellular survival,
and apoptosis, and has been shown to have an inhibitory effect
in many tumor types (Ye et al., 2013; Zhang et al., 2014;
Zheng et al., 2014). However, the inhibitory effect of BMP-2
in tumors is controversial and some studies have shown that
it stimulates tumor growth (Carragee et al., 2013; Liao et al.,
2015), indicating that the action of BMP-2 on tumor growth
probably depends on the cancer type. Most recently, it has
been reported that BMP-2 inhibits tumor growth in human
RCC and induces bone formation (Wang et al., 2012c). This
study revealed that BMP-2 inhibited growth of the ACHN and
Caki-2 cell lines, human RCC cell lines that express three types
of BMP receptors. This anti-proliferative effect seems to be
due to cell cycle arrest in the G1 phase. A follow-up study
demonstrated that BMP-2 could inhibit the tumor-initiating
ability of human renal ALDH+ CSCs, downregulate expression
of embryonic stem cell markers, and upregulate transcription
of osteogenic markers, suggesting that BMP-2 may therefore
represent a beneficial treatment strategy for human RCC by
targeting the CSC-enriched population (Wang et al., 2015).
Mitsui et al. (2015) revealed that impaired regulation of BMP-2
via epigenetic pathways was associated with RCC pathogenesis,
supporting a role for BMP-2 as a therapeutic strategy in RCC.
However, the poor absorption and instability of BMP-2 means
that further research is needed to improve its drugability by
pharmaceutical technologies; this could include PEGylation or
packaging into liposomes or nanoparticles.
ANTIBODY DRUG CONJUGATES (ADCs)
An ADC is comprised of a monoclonal antibody conjugated
to a cytotoxin that specifically binds to cell-surface antigens on
the target cell; it represents a novel method for the treatment
of mRCC (Goldmacher and Kovtun, 2011). Such conjugates
have received significant attention since positive results in
breast cancer were reported for TDM-1 (Kadcyla; Roche), a
conjugate of the monoclonal antibody trastuzumab and the
cytotoxin maytansine (Verma et al., 2012; Dhillon, 2014). SGN-
75, a humanized anti-CD70 monoclonal antibody conjugated to
monomethyl auristatin F (MMAF) through a maleimidocaproyl
(mc) linker (mcMMAF), has been evaluated in a phase 1 clinical
trial for mRCC and for relapsed or refractory non-Hodgkin
lymphoma (NCT01015911)4. Encouraging antitumor activity has
been observed in both mRCC patients and in relapsed/refractory
non-Hodgkin lymphoma patients.
Wilms’ tumor (WT), a common pediatric solid renal tumor,
is formed when renal precursor cells fail to differentiate properly.
Pode-Shakked et al. (2013) successfully isolated and characterized
WT CSCs expressing NCAM from human WT xenografts,
and showed that lorvotuzumab mertansine (mertansine, also
known as DM1, is a derivative of maytansine), an anti-NCAM
antibody/cytotoxic drug conjugate, can dramatically reduce the
expression of NCAM in WT cells from 42 to 5%, in addition to
inducing a significant reduction in the colony forming capacity
4https://clinicaltrials.gov/
of treated cells (Pode-Shakked et al., 2013). A follow-up study
showed that targeting the human NCAM+ cell fraction with
lorvotuzumab-mertansine resulted in the loss of WT CSCs and
induced a reduction in tumor size in the majority of cases, both
in vitro and in vivo, followed by complete tumor degradation
(Figure 3) (Pode-Shakked et al., 2013; Shukrun et al., 2014).
A phase 2 trial evaluating lorvotuzumab-mertansine is ongoing
(NCT02452554). Therefore, it can be concluded that using ADCs
to deplete the stemness properties of CSCs by targeting ligands
on the CSC cell surface may improve the impact of conventional
chemotherapy. This would consequently result in a clinically
relevant benefit for patients.
NANOMEDICAL STRATEGIES
Recently, molecularly directed nanomedicine has become an
appealing option as an RCC targeted therapy. Nanomedical
strategies can control drug delivery and release more efficiently
than other methods. Nanoparticles are high-capacity carriers for
active compounds. They can easily accumulate at tumor sites
due to the high porosity of the tumor vasculature, impaired
lymphatic drainage (known as the enhanced permeability and
retention effect), or the high affinity of the nanoparticle to
markers specifically expressed on cancer cells. The typical
nanomedicine delivery vehicles include liposomes, polymeric
nanoparticles, nucleic acid based nanoparticles, dendrimers,
magnetic nanoparticles, nanoshells, and virus nanoparticles.
LIPOSOMES
Liu et al. (2015a,b) systemically evaluated the in vitro
performance of sorafenib-loaded poly (lactic-co-glycolic
acid) (PLGA) nanoparticles, 1, 2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) liposomes, and hydrophobically
modified chitosan (HMC)-coated DPPC as delivery systems in
the treatment of RCC. The results of this study showed that
sorafenib-loaded PLGA nanoparticles and HMC-coated DPPC
liposomes could kill significantly more tumor cells than sorafenib
alone at lower concentrations; these methods could be further
developed as unique clinical modalities and paired with ablative
particles for synergistic treatments (Liu et al., 2015a,b). Recently,
Kulkarni et al. (2016) showed that liposomes encapsulating a
multi-receptor tyrosine kinase inhibitor (XL184) significantly
increased anti-tumor activity than XL184 alone. They also found
that the mechanism of XL184 liposomes’ anti-tumor activity
is through inhibition of phosphorylation of Met, AKT, and
MAPK pathways in RCC cells (Kulkarni et al., 2016). These
results indicated that use of liposomes for multi-kinase pathways
inhibition may emerge as a promising treatment option for RCC.
In another study, Kibria et al. (2016) addressed the
discrepancy of antitumor effect of PEGylated liposomal
Doxorubicin (PEG-LP (DOX)) in two tumor models. PEG-LP
(DOX) failed to suppress the growth of the RCC OSRC-2
xenograft tumors. However, it could suppress breast cancer
MDA-MB-231 xenograft tumor growth. Furthermore, they
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FIGURE 3 | A strategy to target human NCAM+ cells with lorvotuzumab mertansine. Targeted therapy resulted in loss of Wilms’ tumor CSCs and a
reduction in tumor size in the majority of cases, both in vitro and in vivo, followed by complete tumor degradation.
showed that extracellular matrix (ECM) molecules of MDA-MB-
231 tumor limited the extent of the penetration and distribution
of PEG-LP, which in turn enhancing the delivery of DOX
to tumor vasculature. Therefore, these findings highlight the
unique characteristics of tumor microenvironment that could be
exploited by nanomedicine for developing novel drug delivery
systems (Kibria et al., 2016).
POLYMERIC NANOPARTICLES
Sumitomo et al. (2008) have used polymeric micelles
incorporated with 7-Ethyl-10-hydroxy-camptothecin
(SN38) to treat the RCC xenograft murine model. This
nanoparticle significantly reduced the bulk of tumors
and decreased the metastatic nodule number than free
drug alone (Sumitomo et al., 2008). New studies showed
that CRLX101, a nanoparticle-drug conjugate containing
camptothecin conjugated to a biocompatible cyclodextrin/
polyethylene glycol (PEG) copolymer, is currently being
evaluated pre-clinically and clinically in multiple tumor types
(Gaur et al., 2014; Lin et al., 2016). A phase I trial of CRLX101
in combination with bevacizumab for mRCC therapy has
recently been completed (NCT016259365). The preliminary data
showed that CRLX101 combined with bevacizumab is a safe
treatment in mRCC. This combination fulfilled the protocol’s
predefined threshold for further examination with responses
and prolonged PFS in a heavily pretreated population (Keefe
5https://clinicaltrials.gov/
et al., 2016). A randomized phase II clinical trial in mRCC of this
combination is ongoing (NCT02187302).
Several studies have proposed to target RCC using
nanocarriers, but, to date, these approaches have not been
investigated in renal CSCs. Nanoparticles effectively inhibit
multiple types of CSCs by targeting specific markers, including
ALDH, CD44, and CD133, and/or specific signaling pathways
and other key developmental signaling pathways implicated
in the maintenance of the CSC pool of many tumors (Lu
et al., 2016). Nanomedical strategies for renal CSCs are under
research and development and a comprehensive evaluation of
the approaches should be available soon.
As mentioned above, renal tumors from patients show strong
resistance to conventional anti-cancer drugs such as interferon
α and interleukins. TKIs have significantly improved outcome
in patients with metastatic disease, while drug resistance still
prevails in most patients over time because of the intricate
tumor evasion mechanisms. TRC105 and CXCR4 inhibitors seem
to be the promising drugs for renal tumors underlining the
importance of specific surface markers (CD105 and CXCR4)
of renal CSCs. According to the newly discovery of specific
expression pattern in renal CSCs, some specific markers are
further developed for obtaining the benefits of less resistance
and enhanced therapy. And great interests are emerging to
develop new therapeutic drugs or immunotoxins targeting renal
CSCs based on molecular mechanisms that regulate stem cell
properties. Despite progress being made in developing targeted
strategies for renal cancer and renal CSCs, more approaches
are still need to be explored notwithstanding the numerous
impediments.
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CONCLUSION
Increasing evidence has shown that CSCs play a key role in
cancer drug resistance, radiation therapy resistance, and are
responsible for disease recurrence. With the development of the
CSC hypothesis, new concepts and approaches for eradicating
malignancies have emerged. It has been shown that renal
carcinomas possess CSCs with mesenchymal properties, and
self-renewal and multi-differentiation properties, although a
definitive selection marker for their isolation and targeting
remains to be found. Subpopulations of renal CSCs may
coexist within a heterogeneous tumor, which means that renal
CSC targeting therapy is a complicated science. A vast body
of targeted therapies has been developed, and the systemic
treatment of RCC has advanced in recent years. These advances
have focused on inhibition of the VEGF and mTOR pathways,
markers (such as CD105 and CXCR4), and differentiation of
renal CSCs. During the last few years, numerous new clinical
trials have been undertaken, or are currently recruiting. Even
if obvious limitations exist in reaching renal CSCs in vivo
owing to the inaccessibility of the entire tumor area or
because of the tumor microenvironment, these limitations
may be overcome with the use of ADCs and nanomedical
strategies. Multimodal CSC-targeting strategies combined with
new pathway specific modulators and cytotoxic agents may also
contribute to overcoming the limitations in RCC treatment.
Successful therapeutic exploitation of renal CSCs will help us
to better understand the role of CSCs in different treatment
responses, different stages of disease, and different patients.
Precise identification of renal CSCs populations and the complete
cell hierarchy will enable the accurate characterization of
disease subtypes. This will ultimately lead to more personalized
and targeted therapies. Rationally designed targeting therapy
for RCC unseals new directions for exploration and clinical
investigation and plants the seeds of hope for advanced clinical
care.
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